ENTPD3 and cancer: Analysis of multiple other cancers further showed that both high EVPL and low ENTPD3 expression predicts poor response to immunotherapy, confirming the tissue-wide and disease-wide applicability of EVPL- and ENTPD3-associated immune dysregulation.